■近年来,非小细胞肺癌(NSCLC)的治疗前景取得了重大进展,标志着向靶向药物和免疫检查点抑制剂(ICIs)的转变。然而,化疗仍然是治疗的基石,单独或组合。微管靶向剂,如紫杉烷和长春花生物碱,在早期和晚期NSCLC的临床实践中起着至关重要的作用。
■这篇综述概述了行动机制,现在的意义,以及微管靶向剂(MTA)的前瞻性进展,在第三阶段试验的新组合上有一个特别的亮点。在线数据库PubMed,WebofScience,科克伦图书馆,和ClinicalTrials.gov使用术语“微管靶向剂”和“非小细胞肺癌”或同义词进行搜索,特别关注过去5年的出版物。
■尽管出现了免疫疗法,MTA仍然至关重要,通常与免疫疗法同时或之后使用,尤其是鳞状细胞肺癌。下一代测序扩展了治疗选择,但是缺乏可靠的免疫疗法生物标志物。虽然抗体-药物缀合物(ADC)显示出希望,管理毒性仍然至关重要。在早期阶段,MTA,可能是ICIs,是标准的,而ADC可能在晚期取代传统化疗。然而,MTA在后续生产线或有禁忌症的患者中仍然是必不可少的。
UNASSIGNED: The treatment landscape of non-small cell lung cancer (NSCLC) has seen significant advancements in recent years, marked by a shift toward target agents and immune checkpoint inhibitors (ICIs). However, chemotherapy remains a cornerstone of treatment, alone or in combination. Microtubule-targeting agents, such as taxanes and vinca alkaloids, play a crucial role in clinical practice in both early and advanced settings in NSCLC.
UNASSIGNED: This review outlines the mechanisms of action, present significance, and prospective advancements of microtubule-targeting agents (MTAs), with a special highlight on new combinations in phase 3 trials. The online databases PubMed, Web of Science, Cochrane Library, and ClinicalTrials.gov were searched using the terms \'Microtubule-targeting agents\' and \'non-small cell lung cancer\' or synonyms, with a special focus over the last 5 years of publications.
UNASSIGNED: Despite the emergence of immunotherapy, MTA remains crucial, often used alongside or after immunotherapy, especially in squamous cell lung cancer. Next-generation sequencing expands treatment options, but reliable biomarkers for immunotherapy are lacking. While antibody-drug conjugates (ADCs) show promise, managing toxicities remain vital. In the early stages, MTAs, possibly with ICIs, are standard, while ADCs may replace traditional chemotherapy in the advanced stages. Nevertheless, MTAs remain essential in subsequent lines or for patients with contraindications.